' 
SCIENTIFIC SCORE
Possibly Effective
Based on 39 Researches
7.4
USERS' SCORE
Good
Based on 1 Review
8.6
Supplement Facts
Serving Size: 1 Soft Gel
Amount Per Serving
%DV
Calories
5
Total Fat
0.5 g
1%**
Cholesterol
<5mg
<2%
Vitamin A (from cod live oil and retinyl palmitate)
27 mcg RAE
3%
Vitamin D (as cholecalciferol) (from cod liver oil and cholecalciferol concentrate)
100 mcg (4,000 IU)
500%
Vitamin E (as d-alpha tocopherol)
0.67 mg
4%
Norwegian Cod Liver Oil
500 mg
†
Total Omega-3 fatty Acids☆
115 mg
†
DHA (Docosahexaenoic Acid)☆
50 mg
†
EPA (Eicosapentaenoic Acid)☆
42 mg
†
Top Medical Research Studies
9.5
Eicosapentaenoic acid helps migraines
A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine.
Directly addresses EPA efficacy
We conducted a thorough investigation into how eicosapentaenoic acid (EPA) can impact episodic migraines. In a carefully designed study, we gathered 70 participants who experienced these migraines and divided them into two groups. One group received a high dose of EPA, while the other was given a placebo. This approach ensured that we could see the true effects of EPA without bias.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
Read More
9.5
Omega-3s effectively reduce migraines
High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis: A Network Meta-Analysis.
Directly addresses migraine treatment
We explored the potential of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as effective treatments for preventing migraines. In a comprehensive analysis of 40 randomized controlled trials involving over 6,600 participants, we compared high doses of these omega-3 fatty acids with other commonly prescribed migraine medications.
Our findings revealed that higher dosages of EPA/DHA resulted in significant decreases in both the frequency and severity of migraines compared to a placebo. Specifically, we observed a notable standardized mean difference in migraine frequency and severity, indicating these omega-3s might be a more effective option than current medications.
Moreover, the acceptance rates of this treatment were promising, suggesting that individuals found it easier to tolerate compared to traditional migraine drugs. This evidence supports the idea that high dosage EPA/DHA could be a leading choice for migraine prevention, potentially offering a safer and more effective alternative for many patients.
Our findings revealed that higher dosages of EPA/DHA resulted in significant decreases in both the frequency and severity of migraines compared to a placebo. Specifically, we observed a notable standardized mean difference in migraine frequency and severity, indicating these omega-3s might be a more effective option than current medications.
Moreover, the acceptance rates of this treatment were promising, suggesting that individuals found it easier to tolerate compared to traditional migraine drugs. This evidence supports the idea that high dosage EPA/DHA could be a leading choice for migraine prevention, potentially offering a safer and more effective alternative for many patients.
Read More
9
Vitamin D helps reduce migraines
Vitamin D supplementation for the treatment of migraine: A meta-analysis of randomized controlled studies.
Study highly relevant to migraine
We explored the potential benefits of vitamin D supplementation for treating migraines. Our analysis focused on several randomized controlled trials (RCTs) to examine how effective vitamin D could be in alleviating migraine symptoms.
Through our review, we included six RCTs involving 301 patients. The results were quite promising. Vitamin D supplementation significantly reduced the number of headache attacks per month and the number of headache days experienced by patients. Additionally, it improved the MIDAS score, which measures the impact of migraines on daily life.
However, it's important to note that vitamin D did not show a significant effect on how long migraine attacks lasted or the severity of the headaches. Overall, our findings suggest that while vitamin D might be beneficial for reducing certain migraine-related symptoms, it isn’t a miracle cure for everyone.
Through our review, we included six RCTs involving 301 patients. The results were quite promising. Vitamin D supplementation significantly reduced the number of headache attacks per month and the number of headache days experienced by patients. Additionally, it improved the MIDAS score, which measures the impact of migraines on daily life.
However, it's important to note that vitamin D did not show a significant effect on how long migraine attacks lasted or the severity of the headaches. Overall, our findings suggest that while vitamin D might be beneficial for reducing certain migraine-related symptoms, it isn’t a miracle cure for everyone.
Read More
Most Useful Reviews
9.5
Migraine relief
Very pleased! My doctor in Finland recommended this product a year ago for my Multiple Sclerosis. I take one capsule daily and now feel energetic, no longer tired. Remarkably, my pain has diminished, and I haven’t had the flu this year! The migraine, which previously forced me to use medication every week, has ceased. I am incredibly grateful for this improvement!
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 39 Researches
7.4
- All Researches
9.5
Omega-3s effective for migraine
High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis: A Network Meta-Analysis.
Overall study shows positive results
We dug into how docosahexaenoic acid (DHA), along with eicosapentaenoic acid (EPA), can help with migraine management. Through a comprehensive analysis of 40 randomized controlled trials involving over 6,600 participants, we compared various treatments for migraine prevention. Our focus was on the effectiveness and acceptability of high doses of DHA and EPA against other standard medications.
What we found was quite intriguing. Supplementing with high doses of EPA and DHA significantly reduced the frequency of migraines as compared to placebo treatments. In fact, our analysis revealed a notable decrease in migraine severity as well. Not only that, but those using high-dose omega-3s reported favorable experiences with treatment, showcasing a high level of acceptability.
This compelling evidence suggests that high doses of DHA and EPA can serve as a premier option for preventing migraines. Their effectiveness and tolerability make them an attractive choice for those seeking relief. The potential of omega-3 supplementation in this context opens new avenues for migraine management that are worth exploring further.
What we found was quite intriguing. Supplementing with high doses of EPA and DHA significantly reduced the frequency of migraines as compared to placebo treatments. In fact, our analysis revealed a notable decrease in migraine severity as well. Not only that, but those using high-dose omega-3s reported favorable experiences with treatment, showcasing a high level of acceptability.
This compelling evidence suggests that high doses of DHA and EPA can serve as a premier option for preventing migraines. Their effectiveness and tolerability make them an attractive choice for those seeking relief. The potential of omega-3 supplementation in this context opens new avenues for migraine management that are worth exploring further.
Read More
9.5
Eicosapentaenoic acid helps migraines
A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine.
Directly addresses EPA efficacy
We conducted a thorough investigation into how eicosapentaenoic acid (EPA) can impact episodic migraines. In a carefully designed study, we gathered 70 participants who experienced these migraines and divided them into two groups. One group received a high dose of EPA, while the other was given a placebo. This approach ensured that we could see the true effects of EPA without bias.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
After 12 weeks, the results were compelling. We noticed that those taking EPA had significantly fewer migraine days compared to the placebo group. In fact, participants on EPA reported an average reduction of 4.4 days per month, while those on the placebo had barely any change. The EPA group also experienced less need for acute headache medication and marked improvements in headache severity, disability, anxiety, depression, and overall quality of life.
Perhaps most striking was how particularly beneficial EPA seemed to be for female participants. Overall, the study demonstrated that high-dose EPA not only helped reduce the frequency and severity of migraines but also positively influenced the psychological aspects of living with migraines.
This suggests that incorporating EPA into migraine management could be a valuable option for those suffering from episodic migraines, especially as there were no major adverse effects reported.
Read More
9.5
Omega-3s effectively reduce migraines
High Dosage Omega-3 Fatty Acids Outperform Existing Pharmacological Options for Migraine Prophylaxis: A Network Meta-Analysis.
Directly addresses migraine treatment
We explored the potential of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as effective treatments for preventing migraines. In a comprehensive analysis of 40 randomized controlled trials involving over 6,600 participants, we compared high doses of these omega-3 fatty acids with other commonly prescribed migraine medications.
Our findings revealed that higher dosages of EPA/DHA resulted in significant decreases in both the frequency and severity of migraines compared to a placebo. Specifically, we observed a notable standardized mean difference in migraine frequency and severity, indicating these omega-3s might be a more effective option than current medications.
Moreover, the acceptance rates of this treatment were promising, suggesting that individuals found it easier to tolerate compared to traditional migraine drugs. This evidence supports the idea that high dosage EPA/DHA could be a leading choice for migraine prevention, potentially offering a safer and more effective alternative for many patients.
Our findings revealed that higher dosages of EPA/DHA resulted in significant decreases in both the frequency and severity of migraines compared to a placebo. Specifically, we observed a notable standardized mean difference in migraine frequency and severity, indicating these omega-3s might be a more effective option than current medications.
Moreover, the acceptance rates of this treatment were promising, suggesting that individuals found it easier to tolerate compared to traditional migraine drugs. This evidence supports the idea that high dosage EPA/DHA could be a leading choice for migraine prevention, potentially offering a safer and more effective alternative for many patients.
Read More
9
Vitamin D may alleviate migraines
The association of serum vitamin D concentrations in paediatric migraine.
Focuses on pediatric vitamin D impacts.
We aimed to understand how vitamin D impacts migraine headaches in children. Through a thorough review of existing literature, we explored the significant association between serum vitamin D levels and the frequency and duration of migraine episodes in the pediatric population.
Our findings suggest that children with migraines might benefit from vitamin D supplementation. By potentially reducing the number and intensity of migraine episodes, vitamin D could improve the overall quality of life for these young patients.
It's important to note that this connection primarily focuses on children, as most studies have looked at adults. With vitamin D deficiency being a growing public health concern, our research highlights how addressing this deficiency may serve as a helpful strategy in managing pediatric migraines.
Our findings suggest that children with migraines might benefit from vitamin D supplementation. By potentially reducing the number and intensity of migraine episodes, vitamin D could improve the overall quality of life for these young patients.
It's important to note that this connection primarily focuses on children, as most studies have looked at adults. With vitamin D deficiency being a growing public health concern, our research highlights how addressing this deficiency may serve as a helpful strategy in managing pediatric migraines.
Read More
9
Pediatric migraines and vitamin D
The Impact of Vitamin D Supplementation to Topiramate Therapy on Pediatric Migraine Prophylaxis.
Study on vitamin D's role
We conducted a study to investigate whether adding vitamin D supplements to topiramate therapy would improve migraine outcomes in children aged 5 to 14. In our double-blinded clinical trial, we randomly assigned participants to receive either topiramate with a daily 5000-IU vitamin D supplement or topiramate with a placebo for four months. By evaluating changes in headache frequency, severity, disability, and overall response to treatment, we aimed to see if vitamin D could provide additional benefits.
Our findings were quite promising. The children receiving the vitamin D supplement had a significant reduction in the number of headaches they experienced each month compared to those on placebo. Additionally, the vitamin D group reported less disability due to migraines and a higher percentage of positive treatment responses. Specifically, about 76% of children in the vitamin D group showed a good response, compared to just over 53% in the placebo group.
Safety was assessed as well, with side effects occurring in 13.3% of the vitamin D group and 20% in the placebo group, indicating that vitamin D was well-tolerated. Overall, we believe that combining vitamin D with topiramate represents a safe and potentially effective approach to managing pediatric migraines.
Our findings were quite promising. The children receiving the vitamin D supplement had a significant reduction in the number of headaches they experienced each month compared to those on placebo. Additionally, the vitamin D group reported less disability due to migraines and a higher percentage of positive treatment responses. Specifically, about 76% of children in the vitamin D group showed a good response, compared to just over 53% in the placebo group.
Safety was assessed as well, with side effects occurring in 13.3% of the vitamin D group and 20% in the placebo group, indicating that vitamin D was well-tolerated. Overall, we believe that combining vitamin D with topiramate represents a safe and potentially effective approach to managing pediatric migraines.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.6
- All Reviews
- Positive Reviews
- Negative Reviews
9.5
Migraine relief
Very pleased! My doctor in Finland recommended this product a year ago for my Multiple Sclerosis. I take one capsule daily and now feel energetic, no longer tired. Remarkably, my pain has diminished, and I haven’t had the flu this year! The migraine, which previously forced me to use medication every week, has ceased. I am incredibly grateful for this improvement!
Read More
